TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2473403

Group type: EXPERIMENTAL
Intervention: Encainide or flecainide
Number of subjects: 2309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2309
Study: 604922

Group type: EXPERIMENTAL
Intervention: Social reinforcement procedure for visual attention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no social reinforcement)
Number of subjects: 16
Study: 31318832

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate administration
Number of subjects: 0
Study: 31419610

Group type: EXPERIMENTAL
Intervention: Moment‐by‐Moment in Women's Recovery (MMWR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (time‐matched psychoeducation)
Number of subjects: 200
Study: 28640214

Group type: EXPERIMENTAL
Intervention: Hayward kiwifruit (with actinidin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hort16A kiwifruit (without actinidin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both kiwifruit types
Number of subjects: 10
Study: 26075538

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 64
Study: 23815743

Group type: EXPERIMENTAL
Intervention: MRI findings clusters identified through Latent Class Analysis
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Latent Class Analysis
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 631
Study: 21959095

Group type: EXPERIMENTAL
Intervention: SEEK model training for pediatric residents
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care from control residents
Number of subjects: 95
Study: 19803628

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Concerta)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16446330

Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (TC)
Number of subjects: 798
Study: 12919083

Group type: EXPERIMENTAL
Intervention: Large database analysis in renal transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single center and randomized prospective studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical considerations
Number of subjects: 0
Study: 11019835

Group type: EXPERIMENTAL
Intervention: SCF plus filgrastim (20 microg/kg/day + 10 microg/kg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Filgrastim alone (10 microg/kg/day)
Number of subjects: 102
Study: 8736296

Group type: EXPERIMENTAL
Intervention: Extra-articular reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-articular reconstruction
Number of subjects: 0
Study: 1539754

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) given once every three months for four, eight, or eleven doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) given once every three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated persons)
Number of subjects: 0
Study: 2951792

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of fenoterol and ipratropium bromide
Number of subjects: 10
Study: 31705983

Group type: EXPERIMENTAL
Intervention: Elective TEVAR for DTAA
Number of subjects: 1784
Study: 31095126

Group type: EXPERIMENTAL
Intervention: Normobaric interval hypoxic therapy and enteral oxygen therapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 230
Study: 28419387

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 169
Study: 25809173

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 0
Study: 22939108

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21228265

Group type: EXPERIMENTAL
Intervention: High-salt meal (HSM; 65 mmol Na)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-salt meal (LSM; 5 mmol Na)
Number of subjects: 16
Study: 18602726

Group type: EXPERIMENTAL
Intervention: TIV from multi‐dose vials with thimerosal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TIV from pre‐filled syringes without thimerosal
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17041825

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Quality of movement on the WMFT (functional ability score)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Speed of movement on the WMFT (timed score)
Number of subjects: 39
Study: 12534514

Group type: EXPERIMENTAL
Intervention: Combined Ultrapulse CO2 laser and Q-switched alexandrite laser (QSAL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL) alone
Number of subjects: 6
Study: 15354456

Group type: EXPERIMENTAL
Intervention: 0.42% fluoride gel
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no fluoride gel)
Number of subjects: 27
Study: 9255720

Group type: EXPERIMENTAL
Intervention: NONMEM approach
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: log-likelihood procedure
Number of subjects: 14

Group type: COMPARATOR
Intervention: traditional NONMEM approach
Number of subjects: 14

Group type: COMPARATOR
Intervention: standard approach
Number of subjects: 14

Group type: COMPARATOR
Intervention: standard method
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NONMEM
Number of subjects: 14
Study: 8497343

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 75 micrograms of levonorgestrel
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 150 micrograms of desogestrel
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 10 mg of medroxyprogesterone acetate
Number of subjects: 3
Study: 3305088

Group type: EXPERIMENTAL
Intervention: Potassium salt supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamterene (potassium blocking agent)
Number of subjects: 0
Study: 29338855

Group type: EXPERIMENTAL
Intervention: 200 mg twice daily vaginal Endometrin
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: 50 mg daily intramuscular P only
Number of subjects: 645

Group type: COMPARATOR
Intervention: 200 mg twice daily Endometrin plus 50 mg intramuscular P every 3rd day
Number of subjects: 645
Study: 26908758

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (750 mg) plus miconazole (200 mg) for 5 consecutive nights each month for 12 months
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole plus miconazole
Number of subjects: 234
Study: 24751822

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg iron
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 290
Study: 23412930

Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg daily (n = 58)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (n = 57)
Number of subjects: 115
Study: 20810168

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Control group (survey-only)
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Targeted intervention vs Control group
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Tailored intervention vs Targeted intervention
Number of subjects: 5500
Study: 18440519

Group type: EXPERIMENTAL
Intervention: Recombinant LH 75 IU/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16834833

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 6 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12763318

Group type: EXPERIMENTAL
Intervention: Knowledge-subtyping condition (neutral feature predicts stereotype-congruence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knowledge-standard condition (neutral feature uncorrelated with stereotype-congruence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiment 2 (generalization of effects)
Number of subjects: 0
Study: 10859708

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9543657

Group type: EXPERIMENTAL
Intervention: Families of patients with psychiatric disorders
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control group of nonclinical families
Number of subjects: 353
Study: 8446720

Group type: EXPERIMENTAL
Intervention: Rapid tissue expansion (once a day, starting 1 week postoperatively, for 14 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Slow tissue expansion (once a week, starting after 2 weeks, for 41 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All patients (combined data)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rapid tissue expansion (once a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Slow tissue expansion (once a week)
Number of subjects: 50
Study: 3446535

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) following surgical peripheral iridectomy (PI) or laser iridotomy (LI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No ALT treatment following PI or LI
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Iridoplasty followed by ALT
Number of subjects: 52
Study: 30502778

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including home visits by community health workers, physician education, and text messaging
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 1432
Study: 29071924

Group type: EXPERIMENTAL
Intervention: Heat-reinforcing needling (HRN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (uniform reinforcing-reducing method)
Number of subjects: 60
Study: 24964814

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 22688551

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 90
Study: 20346182

Group type: EXPERIMENTAL
Intervention: 0.03 IU/min vasopressin infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 50
Study: 18714440

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 1730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1730
Study: 20214761

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet
Number of subjects: 322

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem)
Number of subjects: 322
Study: 15585538

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (10 sessions over five months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waiting list for therapy
Number of subjects: 71
Study: 12391340

Group type: EXPERIMENTAL
Intervention: Low-flow ventriculoperitoneal shunt treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study: 10518856

Group type: EXPERIMENTAL
Intervention: Dental floss containing 0.25 mg tetrasodium pyrophosphate per cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo floss
Number of subjects: 0
Study: 8077370

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol administration (100 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo session
Number of subjects: 20
Study: 2644465

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 315
Study: 1228009

Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate in a cream base containing DMSO
Number of subjects: 15
Study: 11327066

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth (OSFM) disinfection treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 31
Study: 31551385

Group type: EXPERIMENTAL
Intervention: SToP activities (seeing, treating, and preventing skin infections)
Number of subjects: 0
Study: 29053861

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 3783

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 3783
Study: 26576663

Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg once daily
Number of subjects: 174

Group type: COMPARATOR
Intervention: MPFF 500 mg twice daily
Number of subjects: 174
Study: 27129012

Group type: EXPERIMENTAL
Intervention: Olokizumab administered intravenously (iv) or subcutaneously (sc)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Olokizumab
Number of subjects: 67
Study: 22744665

Group type: EXPERIMENTAL
Intervention: Fipamezole 90 mg TID
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 19639377

Group type: EXPERIMENTAL
Intervention: Purified black tea theaflavins (TFs) providing 77.5 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Purified black tea theaflavins/catechins (TFs/catechins) providing 75.0 mg TFs plus 150.0 mg catechins and 195.0 mg of other polyphenols
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 102
Study: 17923296

Group type: EXPERIMENTAL
Intervention: Home therapy exercises after carpal tunnel release
Number of subjects: 150

Group type: COMPARATOR
Intervention: Home therapy exercises plus therapist-directed program for 2 weeks
Number of subjects: 150
Study: 15811165

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 36
Study: 12196367

Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual information treatment options
Number of subjects: 83
Study: 10622275

Group type: EXPERIMENTAL
Intervention: 75 mg MDMA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 mg/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: MDMA and alcohol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7860949

Group type: EXPERIMENTAL
Intervention: 300 mg sodium PHT plus 1 mg folic acid per day
Number of subjects: 6

Group type: COMPARATOR
Intervention: 300 mg sodium PHT per day
Number of subjects: 6
Study: 1949301

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (tPA) (100 mg over 3 hours)
Number of subjects: 20981

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) (1.5 MU over one hour)
Number of subjects: 20981

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (12,500 U twice daily)
Number of subjects: 20981

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 20981

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (tPA)
Number of subjects: 20981

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 20981

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 20981
Study: 7031858

Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31498139

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Gait Training (CG)
Number of subjects: 26
Study: 29263366

Group type: EXPERIMENTAL
Intervention: Drisapersen (an antisense oligonucleotide targeting exon 51) in an open label study with 12 patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Drisapersen in a phase 3 randomized, double blind, placebo controlled study involving 186 patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Drisapersen in an open label extension study after the phase 3 study
Number of subjects: 66
Study: 25660483

Group type: EXPERIMENTAL
Intervention: Point-of-decision prompt (PODP) intervention; delivered orally at the beginning and middle of presentations.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PODP intervention).
Number of subjects: 12
Study: 24095896

Group type: EXPERIMENTAL
Intervention: Acute exercise (EX) - cycling for 1 hour at 75% V̇O2peak
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest (REST) - control condition
Number of subjects: 9
Study: 22605362

Group type: EXPERIMENTAL
Intervention: High-empathy group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low-empathy group
Number of subjects: 71
Study: 19183126

Group type: EXPERIMENTAL
Intervention: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
Number of subjects: 0
Study: 17475736

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy plus pharmacotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Clinical management (medication plus intensive clinical management)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 124
Study: 15241750

Group type: EXPERIMENTAL
Intervention: 8-week hip-exercise intervention (strength and postural stability exercises)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Basic isometric and active range of motion exercises (control group)
Number of subjects: 34
Study: 12541094

Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 41
Study: 9579760

Group type: EXPERIMENTAL
Intervention: Asthma Self Management Training (4 training sessions)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Regular care (Control group)
Number of subjects: 303
Study: 7645553

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccination in chronic renal failure patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccination in dialysis patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccination in transplant patients
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (age-matched patients with mild essential hypertension and normal kidney function)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Comparison of antibody concentrations post-vaccination
Number of subjects: 83
Study: 2670027

Group type: EXPERIMENTAL
Intervention: Calcium alginate dressing
Number of subjects: 107

Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 107
Study: 334604

Group type: EXPERIMENTAL
Intervention: Ketoprofen (Orudis) 100 mg suppository nightly for ten days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indomethacin suppository nightly for ten days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient's and doctor's assessment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laboratory examinations
Number of subjects: 60
Study: 31418996

Group type: EXPERIMENTAL
Intervention: Neurofeedback intervention (details not specified)
Number of subjects: 82
Study: 29738168

Group type: EXPERIMENTAL
Intervention: Huobi Powder (12-hour application to the umbilicus, qd for 28 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 72
Study: 25455610

Group type: EXPERIMENTAL
Intervention: PDL + rapamycin
Number of subjects: 23

Group type: COMPARATOR
Intervention: PDL + placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: rapamycin
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 23085040

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Individual Psychotherapy (IP)
Number of subjects: 450
Study: 21362108

Group type: EXPERIMENTAL
Intervention: nabiximols (Sativex) as add-on therapy
Number of subjects: 572
Study: 19258540

Group type: EXPERIMENTAL
Intervention: DFMO/sulindac
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 18164919

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg, 200 mg, and 300 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg and 300 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 15181043

Group type: EXPERIMENTAL
Intervention: 1.0 nM Ang II
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 microM Ang II
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 microM Ang II + 48 microM hydralazine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ringer solution (control)
Number of subjects: 16
Study: 11773991

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg once a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spirapril (both dosages combined)
Number of subjects: 40
Study: 10372580

Group type: EXPERIMENTAL
Intervention: Binary-gamble question for health states (intermittent claudication and major amputation)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Disease-specific vignettes
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Generic vignettes
Number of subjects: 1003
Study: 8556031

Group type: EXPERIMENTAL
Intervention: 35 micrograms of ethinyl estradiol (EE) plus 250 micrograms of norgestimate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 micrograms of ethinyl estradiol (EE) plus 75 micrograms of gestodene
Number of subjects: 40
Study: 2371369

Group type: EXPERIMENTAL
Intervention: 10 mg/day haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 mg/day haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 80 mg/day haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Blood levels of plasma and RBC haloperidol
Number of subjects: 47